IMAXIO S.A.

Founded in 2000, IMAXIO is a biotech company specializing in the field of vaccinology. Owing to his significant scientific and commercial expertise, IMAXIO is active in all stages of the life cycle of vaccines, from development through to market release. IMAXIO is specialised in the prevention of human leptospirosis. IMAXIO has an international business presence, particularly in Asia where the company maintains a partnership for the distribution of the leptospirosis vaccine, and plans to extend its activities into new markets, most notably in Europe via a number of distribution partnerships. For the French market, IMAXIO is open to the establishment of agreements for distribution and product purchasing licenses, whether in the fields of workplace health and safety or travel-related illness.